Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

Stefano Rusconi,Paola Vitiello,Fulvio Adorni,Elisa Colella,Emanuele Focà,Amedeo Capetti,Paola Meraviglia,C. Abeli,Stefano Bonora,Marco D’Annunzio,Antonio Di Biagio,Massimo Di Pietro,L. Butini,Giancarlo Orofino,Manuela Colafigli,Gabriella D'Ettorre,Daniela Francisci,Giustino Parruti,Alessandro Soria,Anna Rita Buonomini,Chiara Tommasi,Silvia Mosti,Francesca Bai,Silvia Di Nardo Stuppino,Manuela Morosi,Marco Montano,Pamela Tau,Esther Merlini,Giulia Marchetti

Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

2013

Background: Immunological non-responders (INRs) lacked CD4 increase despite HIV-viremia suppression on HAART and had an increased risk of disease progression. We assessed immune reconstitution profile upon intensification with maraviroc in INRs.

Keywords:

Randomized controlled trial
Cytotoxic T cell
Immune system
Maraviroc
Disease
Immunology
Flow cytometry
Biology
Viral load
disease progression
increased risk
Oncology
human immunodeficiency virus
treatment outcome
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations